13523: Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with metastatic leiomyosarcoma. Participants are being invited to participate in this research study because they have metastatic leiomyosarcoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854591
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
